sales and marketing news from FierceBiotech
News
Developers look for rules to govern name game
The RPM Report focuses on a new effort to revise and improve the way the FDA approves proposed proprietary drug names. The agency kicks back about 40 percent of the brand names suggested by sponsors, Read more...
ALSO NOTED: ASCO already churning out news; Lilly, FDA ironing out Zyprexa shot problems; and much more...
> Today marks the start of the annual ASCO. Here's a round-up of some of the news coming out of the conference. Read more...
Medivir could gain $430M from HCV collaboration
BioWorld examines a $430 million deal between Sweden's Medivir and Tibotec to develop new polymerase inhibitors. They'll jointly screen libraries for nucleoside analogues that show anti-HCV activity Read more...
SPOTLIGHT: Novalar approval a small gain for big group
Novalar Pharmaceuticals may not have made drug history when the FDA approved their new therapy to speed the return of sensation after dental procedures, but the private biotech has some ambitious Read more...
FDA staffers say that Eisai sedative appears safe
FDA staffers say that an experimental sedative developed by Eisai appears to be safe, but wants outside experts to consider whether it's safe enough to be administered by workers untrained in Read more...
SPOTLIGHT: J&J chops jobs
With Procrit under siege, Johnson & Johnson wants to divert its promotional efforts elsewhere--a strategy that will lead to some 400 job cuts in its sales-and-marketing ranks. The company told Read more...
U.S. R&D headcount tumbles in key categories
Pharmalot has been crunching the numbers for R&D jobs and concludes that the U.S. is seeing a considerable amount of shrinkage in the field. Looking at new numbers from PhRMA for 2006, R&D Read more...
Cell Therapeutics reorganizes, scales back R&D
Cell Therapeutics is scaling back its research plans for Xyotax and pixantrone, cutting one group of Read more...
HGS stock dives on drug safety concerns
Human Genome Sciences watched its stock take a dive this morning after an independent data monitoring committee noted lung-related side effects in patients receiving 1200-microgram injections of the Read more...
ALSO NOTED: Cardiome awaits FDA decision; Congress to investigate Vytorin scandal; and much more...
> Cardiome is awaiting a critical FDA decision on its drug vernakalant. Report > It seems that many black U.S. residents Read more...
Get more sales and marketing coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets